MaxCyte, Inc. (MXCT) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.54
↓-75% vs avg
5yr avg: 2.17
30Y Low1.0·High3.5
ROE
↓
-23.6%
↑-48% vs avg
5yr avg: -16.0%
30Y Low-334%·High-9%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MXCT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
MaxCyte, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $93M | $165M | $436M | $485M | $555M | $923M | — | — | — | — | — |
| Enterprise Value | $91M | $163M | $426M | $458M | $560M | $881M | — | — | — | — | — |
| P/E Ratio → | -2.08 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.81 | 4.99 | 11.29 | 11.76 | 12.55 | 27.24 | — | — | — | — | — |
| P/B Ratio | 0.54 | 0.96 | 2.11 | 2.09 | 2.19 | 3.51 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MXCT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.93 | 11.04 | 11.08 | 12.66 | 26.00 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
MXCT Profitability
Margins and return-on-capital ratios measuring operating efficiency
MaxCyte, Inc. earns an operating margin of -138.3%. Operating margins have compressed from -117.0% to -138.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -23.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.2% | 81.2% | 81.6% | 88.5% | 88.5% | 89.2% | 89.4% | 88.4% | 89.0% | 89.6% | 89.3% |
| Operating Margin | -138.3% | -138.3% | -132.5% | -117.0% | -61.8% | -53.7% | -42.3% | -57.4% | -50.5% | -66.4% | -22.2% |
| Net Profit Margin | -135.1% | -135.1% | -106.3% | -91.8% | -53.3% | -56.3% | -45.2% | -59.6% | -53.2% | -70.9% | -27.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -23.6% | -23.6% | -18.7% | -15.6% | -9.1% | -12.9% | -50.5% | -99.6% | -55.6% | -80.4% | -334.4% |
| ROA | -20.2% | -20.2% | -16.2% | -13.7% | -8.3% | -11.4% | -28.9% | -47.5% | -31.9% | -41.8% | -29.8% |
| ROIC | -18.7% | -18.7% | -19.2% | -15.6% | -8.6% | -11.3% | -61.3% | -159.3% | -235.1% | — | — |
| ROCE | -22.2% | -22.2% | -21.6% | -18.5% | -10.1% | -11.8% | -36.4% | -64.8% | -40.3% | -53.7% | -46.4% |
MXCT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $20M exceeds total debt of $18M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.09 | 0.08 | 0.06 | 0.02 | 0.21 | 0.53 | 0.41 | 0.26 | 0.98 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.01 | -0.05 | -0.12 | 0.02 | -0.16 | -0.35 | -0.59 | -0.50 | -1.04 | -1.32 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -215.61 | -17.42 | -13.39 | -18.24 | -13.71 | -14.86 | -4.27 |
Net cash position: cash ($20M) exceeds total debt ($18M)
MXCT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
MaxCyte, Inc.'s current ratio of 8.30x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 7.77x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 10.65x to 8.30x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.30 | 8.30 | 10.88 | 10.65 | 16.35 | 17.32 | 3.90 | 2.62 | 3.42 | 4.22 | 2.79 |
| Quick Ratio | 7.77 | 7.77 | 10.32 | 9.97 | 15.80 | 16.98 | 3.52 | 2.22 | 3.07 | 4.03 | 2.56 |
| Cash Ratio | 1.41 | 1.41 | 9.79 | 9.43 | 14.74 | 16.33 | 2.99 | 1.79 | 2.20 | 3.50 | 2.07 |
| Asset Turnover | — | 0.16 | 0.16 | 0.15 | 0.15 | 0.12 | 0.51 | 0.72 | 0.69 | 0.45 | 0.76 |
| Inventory Turnover | 0.82 | 0.82 | 0.80 | 0.39 | 0.59 | 0.70 | 0.64 | 0.68 | 0.82 | 1.08 | 0.98 |
| Days Sales Outstanding | — | 38.71 | 44.24 | 51.08 | 92.16 | 74.06 | 72.14 | 54.77 | 107.41 | 83.40 | 71.71 |
MXCT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
MaxCyte, Inc. returns 0.2% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.2% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.2% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $106M | $105M | $103M | $102M | $91M | $69M | $56M | $51M | $49M | $34M |
Peer Comparison
Compare MXCT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MXCTYou | $93M | -2.1 | — | — | 81.2% | -138.3% | -23.6% | -18.7% | — |
 BTBT | $589M | 9.2 | 8.5 | — | 61.9% | 16.8% | 9.2% | 6.5% | 0.2 |
 LNTH | $6B | 26.7 | 14.6 | 16.7 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 PSNL | $532M | -6.6 | — | — | — | — | -35.0% | -40.7% | — |
 BCYC | $339M | -1.5 | — | — | 100.0% | -341.3% | -31.2% | — | — |
 XNCR | $903M | -9.9 | — | — | 91.6% | -141.4% | -14.0% | -16.3% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See MXCT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MXCT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MXCT vs BTBT
Side-by-side business, growth, and profitability comparison vs Bit Digital, Inc..
Start ComparisonMXCT — Frequently Asked Questions
Quick answers to the most common questions about buying MXCT stock.
What is MaxCyte, Inc.'s P/E ratio?
MaxCyte, Inc.'s current P/E ratio is -2.1x. This places it at the 50th percentile of its historical range.
What is MaxCyte, Inc.'s ROE?
MaxCyte, Inc.'s return on equity (ROE) is -23.6%. The historical average is -70.0%.
Is MXCT stock overvalued?
Based on historical data, MaxCyte, Inc. is trading at a P/E of -2.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are MaxCyte, Inc.'s profit margins?
MaxCyte, Inc. has 81.2% gross margin and -138.3% operating margin.